Contraception News and Research RSS Feed - Contraception News and Research

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Bayer expands patient assistance program for intrauterine devices

Bayer expands patient assistance program for intrauterine devices

Bayer HealthCare Pharmaceuticals Inc. today announced the expansion of its patient assistance program for intrauterine devices (IUD). The ARCH (Access and Resources for Contraceptive Health) program will provide Skyla (levonorgestrel-releasing intrauterine system) 13.5 mg and Mirena (levonorgestrel-releasing intrauterine system) 52 mg to low-income women who meet eligibility criteria. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). [More]
Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Catholics for Choice calls on Pope Francis to open childcare facilities in Vatican City

Today, in light of Pope Francis' comments that he believes "not having children is a selfish choice,"Catholics for Choice suggests that the pope, cardinals, bishops and priests that make up the citizens of Vatican City consider opening and running childcare facilities for the women in the world to give the hierarchy some hands-on experience. [More]
LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

LA BioMed's Christina Wang receives Mayo H. Soley Award for outstanding research work

Christina Wang, MD, Los Angeles Biomedical Research Institute lead researcher, has received a top honor for her outstanding research work, the Mayo H. Soley Award, at the 2015 Western Regional Meetings of five top research societies in the West. [More]
Providing knowledge about contraception can significantly improve use of isotretinoin

Providing knowledge about contraception can significantly improve use of isotretinoin

Providing women who take a powerful acne drug with a fact sheet about contraception while visiting the dermatologist can significantly improve their awareness of the most effective birth control options and may prevent unintended pregnancies and birth defects that can be caused by the drug, according to a University of Pittsburgh School of Medicine study published Feb. 4 in the journal JAMA Dermatology. [More]
News study finds association between chronic fatigue syndrome and early menopause

News study finds association between chronic fatigue syndrome and early menopause

A newfound link between chronic fatigue syndrome (CFS) and early menopause was reported online today in Menopause, the journal of The North American Menopause Society. [More]
Taking hormonal contraceptives for five years doubles brain tumour risk

Taking hormonal contraceptives for five years doubles brain tumour risk

Taking a hormonal contraceptive for at least five years is associated with a possible increase in a young woman's risk of developing a rare tumour, glioma of the brain. This project focussed on women aged 15 -49 years and the findings are published in the British Journal of Clinical Pharmacology. [More]
AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie gets European Commission's approval to market VIEKIRAX + EXVIERA for HCV treatment

AbbVie announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets). The treatment has been approved with or without ribavirin (RBV) for patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients. [More]
Injectable hormonal contraceptive appears to increase HIV risk in women

Injectable hormonal contraceptive appears to increase HIV risk in women

Women using depot medroxyprogesterone acetate (DMPA), commonly known as Depo-Provera or the birth control shot, have a moderately increased risk of becoming infected with HIV, a large meta-analysis of 12 studies involving more than 39 500 women published in The Lancet Infectious Diseases has found. Other forms of hormonal contraception, including oral contraceptive pills, do not appear to increase this risk. [More]
Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

Abbvie’s HOLKIRA PAK for chronic genotype 1 Hepatitis C treatment receives Health Canada approval

AbbVie receives Health Canada approval for HOLKIRA PAK (ombitasvir/paritaprevir/ritonavir film-coated tablets; dasabuvir film-coated tablets), an all-oral, short-course (12 weeks for the majority of patients), interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with cirrhosis. [More]
Research outlines new model for measuring acceptability of contraceptive vaginal ring

Research outlines new model for measuring acceptability of contraceptive vaginal ring

The Population Council published new research in the November issue of the journal Contraception demonstrating that an investigational one-year contraceptive vaginal ring containing Nestorone and ethinyl estradiol was found to be highly acceptable among women enrolled in a Phase 3 clinical trial. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. [More]
New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

New NIH funding to help researchers develop drug delivery system to prevent HIV infection in women

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million. [More]
FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. [More]
Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan announces U.S. launch of generic Loestrin 24 Fe

Mylan Inc. today announced the U.S. launch of its Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate, which is the generic version of Warner Chilcott's Loestrin 24 Fe. [More]
State exchanges gird for round two

State exchanges gird for round two

Covered California hopes to enroll more than half a million new residents this year, bringing total participants to about 1.7 million. [More]
Research roundup: Malpractice reforms and doctors' practice; Medicaid expansion's effect

Research roundup: Malpractice reforms and doctors' practice; Medicaid expansion's effect

Defensive medicine is considered by many to be a major source of wasteful medical spending in the United States. [More]